Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LA-EP2006 versus Neulasta in breast cancer patients receiving TAC chemotherapy
2012-002039-28Phase 3Completed
- Sponsor
- Sandoz
- Start
- Jul 2012
- Modality
- Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of pegfilgrastim-bmez and pegfilgrastim in breast cancer (2 arms), sponsored by Sandoz. Primary endpoint: Mean duration of severe neutropenia in Cycle 1. Started Jul 2012; status: completed.
02
Drugs
pegfilgrastim-bmezpegfilgrastim
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2012-002039-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002039-28.